A comprehensive review of both animal and human studies finds mixed evidence for THC and CBD as pain treatments, with effectiveness varying by cannabinoid type, delivery method, and pain condition — highlighting the need for more rigorous clinical trials.
Pain patients considering cannabis, pain management physicians, cannabis researchers, and anyone seeking evidence-based information on cannabinoids and pain.
What the researchers found
While preclinical models consistently show cannabinoid analgesic effects, human studies produce largely mixed results that depend on the specific cannabinoid, route of administration, and pain modality tested — with the current evidence insufficient to make definitive clinical recommendations.
Why it matters
Millions of people use cannabis for pain, but this review reveals that the scientific evidence is far more nuanced than either advocates or critics suggest — with significant gaps in our understanding.
The numbers in context
Reviews preclinical, laboratory, and clinical evidence; covers multiple pain modalities (acute, chronic, neuropathic, inflammatory); examines oral, inhaled, and topical cannabinoid routes
How the study worked
Comprehensive narrative review covering pain neurobiology, experimental pain paradigms, preclinical animal models, human laboratory studies, and clinical trials of THC and CBD for various pain conditions.
What this study cannot tell us
Narrative review format with potential selection bias; heterogeneous studies make comparisons difficult; preclinical findings often don't translate to humans; many clinical studies have small samples or lack adequate controls.
How to read the evidence
Authoritative review synthesizing diverse evidence, but the underlying studies vary widely in quality and the overall evidence remains inconclusive for most pain conditions.
When this study was published
Published 2026; covers the latest research on cannabinoids and pain.
The bigger picture
Despite widespread use of cannabis for pain, the evidence base remains surprisingly incomplete — more rigorous placebo-controlled research and investigation of minor cannabinoids and terpenes are urgently needed.
Questions still open
- Could minor cannabinoids or terpenes provide better pain relief than THC or CBD alone? How do cannabinoid-opioid interactions affect pain management? What are the optimal dosing strategies for different pain conditions?
Common questions
Does cannabis work for pain?
Is THC or CBD better for pain?
Read the original research
Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.
Current topics in behavioral neurosciences, 76, 389-431
Citation
Harris, H M; Moore, C F; Jenkins, B W; Bedillion, M F; Weerts, E M; Arout, C A. (2026). Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.. Current topics in behavioral neurosciences, 76, 389-431. https://doi.org/10.1007/7854_2025_604
Explore the wider topic
- THC Purity and Potency: What the Label Actually Means
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?
- THC and Painkillers: Opioid Interactions and the Harm Reduction Angle
- THC and Ibuprofen: Safe to Combine? What the Research Says